Cargando…
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
BACKGROUND: Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety...
Autores principales: | Cortegiani, A., Ippolito, M., Greco, M., Granone, V., Protti, A., Gregoretti, C., Giarratano, A., Einav, S., Cecconi, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369580/ https://www.ncbi.nlm.nih.gov/pubmed/32713784 http://dx.doi.org/10.1016/j.pulmoe.2020.07.003 |
Ejemplares similares
-
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
por: Cortegiani, A., et al.
Publicado: (2021) -
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
por: Cortegiani, Andrea, et al.
Publicado: (2020) -
Chloroquine for COVID-19: rationale, facts, hopes
por: Cortegiani, Andrea, et al.
Publicado: (2020) -
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
por: Cortegiani, Andrea, et al.
Publicado: (2020) -
Mortality after in-hospital cardiac arrest in patients with COVID-19: A systematic review and meta-analysis
por: Ippolito, Mariachiara, et al.
Publicado: (2021)